Researchers from Mayo Clinic have developed a new risk model for myelodysplastic syndrome (MDS). The genetics-based prognostic tool replaces a precursor that was based on the revised International Prognostic Scoring System, which has limited value because it lacks information on mutations and overall complexity of disease.
“Current drug therapy for myelodysplastic syndrome is not curative and is often instituted to palliate anemia and other symptoms,” said Ayalew Tefferi, MD, a